1. Home
  2. KPTI vs GDO Comparison

KPTI vs GDO Comparison

Compare KPTI & GDO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • KPTI
  • GDO
  • Stock Information
  • Founded
  • KPTI 2008
  • GDO 2009
  • Country
  • KPTI United States
  • GDO United States
  • Employees
  • KPTI N/A
  • GDO N/A
  • Industry
  • KPTI Biotechnology: Pharmaceutical Preparations
  • GDO Finance Companies
  • Sector
  • KPTI Health Care
  • GDO Finance
  • Exchange
  • KPTI Nasdaq
  • GDO Nasdaq
  • Market Cap
  • KPTI 81.1M
  • GDO 84.5M
  • IPO Year
  • KPTI 2013
  • GDO N/A
  • Fundamental
  • Price
  • KPTI $0.63
  • GDO $11.49
  • Analyst Decision
  • KPTI Strong Buy
  • GDO
  • Analyst Count
  • KPTI 4
  • GDO 0
  • Target Price
  • KPTI $5.00
  • GDO N/A
  • AVG Volume (30 Days)
  • KPTI 694.6K
  • GDO 39.4K
  • Earning Date
  • KPTI 02-27-2025
  • GDO 01-01-0001
  • Dividend Yield
  • KPTI N/A
  • GDO 9.81%
  • EPS Growth
  • KPTI N/A
  • GDO N/A
  • EPS
  • KPTI N/A
  • GDO N/A
  • Revenue
  • KPTI $148,442,000.00
  • GDO N/A
  • Revenue This Year
  • KPTI $5.47
  • GDO N/A
  • Revenue Next Year
  • KPTI $6.33
  • GDO N/A
  • P/E Ratio
  • KPTI N/A
  • GDO N/A
  • Revenue Growth
  • KPTI 1.77
  • GDO N/A
  • 52 Week Low
  • KPTI $0.58
  • GDO $11.21
  • 52 Week High
  • KPTI $1.70
  • GDO $13.04
  • Technical
  • Relative Strength Index (RSI)
  • KPTI 46.51
  • GDO 61.66
  • Support Level
  • KPTI $0.60
  • GDO $11.20
  • Resistance Level
  • KPTI $0.70
  • GDO $11.29
  • Average True Range (ATR)
  • KPTI 0.05
  • GDO 0.07
  • MACD
  • KPTI -0.00
  • GDO 0.03
  • Stochastic Oscillator
  • KPTI 46.61
  • GDO 100.00

About KPTI Karyopharm Therapeutics Inc.

Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.

About GDO Western Asset Global Corporate Defined Opportunity Fund Inc.

Western Asset Global Corp Defined Opp is a closed-end management investment company with a primary investment objective to provide current income. Its secondary objective is to seek capital appreciation. The Fund invests in the United States and foreign corporate fixed-income securities of varying maturities.

Share on Social Networks: